Skip to main content
Top
Published in: Clinical Research in Cardiology 8/2019

Open Access 01-08-2019 | Opioids | Original Paper

Proenkephalin and prognosis in heart failure with preserved ejection fraction: a GREAT network study

Authors: Prathap Kanagala, Iain B. Squire, Donald J. L. Jones, Thong Huy Cao, Daniel C. S. Chan, Gerry McCann, Jatinderpal K. Sandhu, Paulene A. Quinn, John McAdam, Anna-Marie Marsh, Joan E. Davies, Joachim Struck, Andreas Bergmann, Zaid Sabti, Raphael Twerenbold, Thomas Herrmann, Nikola Kozhuharov, Christian Mueller, Leong L. Ng, On behalf of the GREAT (Global REsearch on Acute Conditions Team) Network

Published in: Clinical Research in Cardiology | Issue 8/2019

Login to get access

Abstract

Background

Proenkephalin (PENK), a stable endogenous opioid biomarker related to renal function, has prognostic utility in acute and chronic heart failure. We investigated the prognostic utility of PENK in heart failure with preserved ejection fraction (HFpEF), and its relationship to renal function, Body Mass Index (BMI), and imaging measures of diastolic dysfunction.

Methods

In this multicentre study, PENK was measured in 522 HFpEF patients (ejection fraction > 50%, 253 male, mean age 76.13 ± 10.73 years) and compared to 47 age and sex-matched controls. The primary endpoint was 2-years composite of all-cause mortality and/or heart failure rehospitalisation (HF). A subset (n = 163) received detailed imaging studies.

Results

PENK levels were raised in HFpEF (median [interquartile range] 88.9 [62.1–132.0]) compared to normal controls (56.3 [47.9–70.5]). PENK was correlated to urea, eGFR, Body Mass Index and E/e′ (rs 0.635, − 0.741, − 0.275, 0.476, respectively, p < 0.0005). During 2 years follow-up 144 patients died and 220 had death/HF endpoints. Multivariable Cox regression models showed PENK independently predicted 2 year death/HF [hazard ratio (for 1 SD increment of log-transformed biomarker) HR 1.45 [95% CI 1.12–1.88, p = 0.005]], even after adjustment for troponin (HR 1.59 [1.14–2.20, p = 0.006]), and Body Mass Index (HR 1.63 [1.13–2.33, p = 0.009]). PENK showed no interaction with ejection fraction status for prediction of poor outcomes. Net reclassification analyses showed PENK significantly improved classification of death/HF outcomes for multivariable models containing natriuretic peptide, troponin and Body Mass Index (p < 0.05 for all).

Conclusions

In HFpEF, PENK levels are related to BMI, and measures of diastolic dysfunction and are prognostic for all-cause mortality and heart failure rehospitalisation.
Appendix
Available only for authorised users
Literature
1.
go back to reference Owan TE, Hodge DO, Herges RM et al (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355(3):251–259CrossRefPubMed Owan TE, Hodge DO, Herges RM et al (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355(3):251–259CrossRefPubMed
2.
go back to reference Meta-analysis Global Group in Chronic Heart F (2012) The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J 33(14):1750–1757CrossRef Meta-analysis Global Group in Chronic Heart F (2012) The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J 33(14):1750–1757CrossRef
3.
go back to reference Cheng JM, Akkerhuis KM, Battes LC et al (2013) Biomarkers of heart failure with normal ejection fraction: a systematic review. Eur J Heart Fail 15(12):1350–1362CrossRefPubMed Cheng JM, Akkerhuis KM, Battes LC et al (2013) Biomarkers of heart failure with normal ejection fraction: a systematic review. Eur J Heart Fail 15(12):1350–1362CrossRefPubMed
4.
go back to reference Anand IS, Rector TS, Cleland JG et al (2011) Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail 4(5):569–577CrossRefPubMed Anand IS, Rector TS, Cleland JG et al (2011) Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail 4(5):569–577CrossRefPubMed
5.
go back to reference Tschöpe C, Birner C, Böhm M et al (2018) Heart failure with preserved ejection fraction: current management and future strategies: expert opinion on the behalf of the nucleus of the “Heart Failure Working Group” of the German Society of Cardiology (DKG). Clin Res Cardiol 107:1–19CrossRefPubMed Tschöpe C, Birner C, Böhm M et al (2018) Heart failure with preserved ejection fraction: current management and future strategies: expert opinion on the behalf of the nucleus of the “Heart Failure Working Group” of the German Society of Cardiology (DKG). Clin Res Cardiol 107:1–19CrossRefPubMed
6.
go back to reference Arbit B, Marston N, Shah K et al (2016) Prognostic usefulness of proenkephalin in stable ambulatory patients with heart failure. Am J Cardiol 117(8):1310–1314CrossRefPubMed Arbit B, Marston N, Shah K et al (2016) Prognostic usefulness of proenkephalin in stable ambulatory patients with heart failure. Am J Cardiol 117(8):1310–1314CrossRefPubMed
7.
go back to reference Doehner W, von Haehling S, Suhr J et al (2012) Elevated plasma levels of neuropeptide proenkephalin a predict mortality and functional outcome in ischemic stroke. J Am Coll Cardiol 60(4):346–354CrossRefPubMed Doehner W, von Haehling S, Suhr J et al (2012) Elevated plasma levels of neuropeptide proenkephalin a predict mortality and functional outcome in ischemic stroke. J Am Coll Cardiol 60(4):346–354CrossRefPubMed
8.
go back to reference Ng LL, Sandhu JK, Narayan H et al (2014) Proenkephalin and prognosis after acute myocardial infarction. J Am Coll Cardiol 63(3):280–289CrossRefPubMed Ng LL, Sandhu JK, Narayan H et al (2014) Proenkephalin and prognosis after acute myocardial infarction. J Am Coll Cardiol 63(3):280–289CrossRefPubMed
9.
go back to reference Ng LL, Squire IB, Jones DJ et al (2017) Proenkephalin, renal dysfunction, and prognosis in patients with acute heart failure: a GREAT network study. J Am Coll Cardiol 69(1):56–69CrossRefPubMed Ng LL, Squire IB, Jones DJ et al (2017) Proenkephalin, renal dysfunction, and prognosis in patients with acute heart failure: a GREAT network study. J Am Coll Cardiol 69(1):56–69CrossRefPubMed
10.
go back to reference Shah KS, Taub P, Patel M et al (2015) Proenkephalin predicts acute kidney injury in cardiac surgery patients. Clin Nephrol 83(1):29–35CrossRefPubMed Shah KS, Taub P, Patel M et al (2015) Proenkephalin predicts acute kidney injury in cardiac surgery patients. Clin Nephrol 83(1):29–35CrossRefPubMed
11.
12.
go back to reference Denning GM, Ackermann LW, Barna TJ et al (2008) Proenkephalin expression and enkephalin release are widely observed in non-neuronal tissues. Peptides 29(1):83–92CrossRefPubMed Denning GM, Ackermann LW, Barna TJ et al (2008) Proenkephalin expression and enkephalin release are widely observed in non-neuronal tissues. Peptides 29(1):83–92CrossRefPubMed
13.
go back to reference Ernst A, Kohrle J, Bergmann A (2006) Proenkephalin A 119–159, a stable proenkephalin A precursor fragment identified in human circulation. Peptides 27(7):1835–1840CrossRefPubMed Ernst A, Kohrle J, Bergmann A (2006) Proenkephalin A 119–159, a stable proenkephalin A precursor fragment identified in human circulation. Peptides 27(7):1835–1840CrossRefPubMed
14.
go back to reference Lofman I, Szummer K, Dahlstrom U et al (2017) Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction. Eur J Heart Fail 19(12):1606–1614CrossRefPubMed Lofman I, Szummer K, Dahlstrom U et al (2017) Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction. Eur J Heart Fail 19(12):1606–1614CrossRefPubMed
15.
go back to reference Ponikowski P, Voors AA, Anker SD et al (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37(27):2129–2200CrossRefPubMed Ponikowski P, Voors AA, Anker SD et al (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37(27):2129–2200CrossRefPubMed
16.
go back to reference Schiller NB, Shah PM, Crawford M et al (1989) Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2(5):358–367CrossRefPubMed Schiller NB, Shah PM, Crawford M et al (1989) Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2(5):358–367CrossRefPubMed
17.
go back to reference Singh A, Greenwood JP, Berry C et al (2017) Comparison of exercise testing and CMR measured myocardial perfusion reserve for predicting outcome in asymptomatic aortic stenosis: the PRognostic Importance of MIcrovascular Dysfunction in Aortic Stenosis (PRIMID AS) Study. Eur Heart J 38(16):1222–1229CrossRefPubMedPubMedCentral Singh A, Greenwood JP, Berry C et al (2017) Comparison of exercise testing and CMR measured myocardial perfusion reserve for predicting outcome in asymptomatic aortic stenosis: the PRognostic Importance of MIcrovascular Dysfunction in Aortic Stenosis (PRIMID AS) Study. Eur Heart J 38(16):1222–1229CrossRefPubMedPubMedCentral
18.
go back to reference Gulati A, Ismail TF, Jabbour A et al (2013) Clinical utility and prognostic value of left atrial volume assessment by cardiovascular magnetic resonance in non-ischaemic dilated cardiomyopathy. Eur J Heart Fail 15(6):660–670CrossRefPubMed Gulati A, Ismail TF, Jabbour A et al (2013) Clinical utility and prognostic value of left atrial volume assessment by cardiovascular magnetic resonance in non-ischaemic dilated cardiomyopathy. Eur J Heart Fail 15(6):660–670CrossRefPubMed
19.
go back to reference Ng LL, Geeranavar S, Jennings SC et al (2004) Diagnosis of heart failure using urinary natriuretic peptides. Clin Sci 106(2):129–133CrossRefPubMed Ng LL, Geeranavar S, Jennings SC et al (2004) Diagnosis of heart failure using urinary natriuretic peptides. Clin Sci 106(2):129–133CrossRefPubMed
20.
go back to reference Pencina MJ, D’Agostino RB, Steyerberg S EW (2011) Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 30(1):11–21CrossRefPubMed Pencina MJ, D’Agostino RB, Steyerberg S EW (2011) Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 30(1):11–21CrossRefPubMed
21.
22.
go back to reference Wienbergen H, Pfister O, Hochadel M, Fach A, Backhaus T, Bruder O, Remppis BA, Maeder MT, von Scheidt W, Pauschinger M, Senges J, Hambrecht R (2018) Long-term effects of iron deficiency in patients with heart failure with or without anemia: the RAID-HF follow-up study. Clin Res Cardiol. https://doi.org/10.1007/s00392-018-1327-y (Epub ahead of print, PMID: 30003365) CrossRefPubMed Wienbergen H, Pfister O, Hochadel M, Fach A, Backhaus T, Bruder O, Remppis BA, Maeder MT, von Scheidt W, Pauschinger M, Senges J, Hambrecht R (2018) Long-term effects of iron deficiency in patients with heart failure with or without anemia: the RAID-HF follow-up study. Clin Res Cardiol. https://​doi.​org/​10.​1007/​s00392-018-1327-y (Epub ahead of print, PMID: 30003365) CrossRefPubMed
23.
go back to reference Pencina MJ, D’Agostino RB, Vasan RS (2010) Statistical methods for assessment of added usefulness of new biomarkers. Clin Chem Lab Med 48:1703–1711CrossRefPubMedPubMedCentral Pencina MJ, D’Agostino RB, Vasan RS (2010) Statistical methods for assessment of added usefulness of new biomarkers. Clin Chem Lab Med 48:1703–1711CrossRefPubMedPubMedCentral
24.
go back to reference Holaday JW (1983) Cardiovascular effects of endogenous opiate systems. Annu Rev Pharmacol Toxicol 23:541–594CrossRefPubMed Holaday JW (1983) Cardiovascular effects of endogenous opiate systems. Annu Rev Pharmacol Toxicol 23:541–594CrossRefPubMed
25.
go back to reference Nencini P, Paroli E (1981) The lipolytic activity of met-enkephalin, leu-enkephalin, morphine, methadone and naloxone in human adipose tissue. Pharmacol Res Commun 13(6):535–540CrossRefPubMed Nencini P, Paroli E (1981) The lipolytic activity of met-enkephalin, leu-enkephalin, morphine, methadone and naloxone in human adipose tissue. Pharmacol Res Commun 13(6):535–540CrossRefPubMed
26.
go back to reference Brestoff JR, Kim BS, Saenz SA et al (2015) Group 2 innate lymphoid cells promote beiging of white adipose tissue and limit obesity. Nature 519(7542):242–246CrossRefPubMed Brestoff JR, Kim BS, Saenz SA et al (2015) Group 2 innate lymphoid cells promote beiging of white adipose tissue and limit obesity. Nature 519(7542):242–246CrossRefPubMed
Metadata
Title
Proenkephalin and prognosis in heart failure with preserved ejection fraction: a GREAT network study
Authors
Prathap Kanagala
Iain B. Squire
Donald J. L. Jones
Thong Huy Cao
Daniel C. S. Chan
Gerry McCann
Jatinderpal K. Sandhu
Paulene A. Quinn
John McAdam
Anna-Marie Marsh
Joan E. Davies
Joachim Struck
Andreas Bergmann
Zaid Sabti
Raphael Twerenbold
Thomas Herrmann
Nikola Kozhuharov
Christian Mueller
Leong L. Ng
On behalf of the GREAT (Global REsearch on Acute Conditions Team) Network
Publication date
01-08-2019
Publisher
Springer Berlin Heidelberg
Published in
Clinical Research in Cardiology / Issue 8/2019
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-019-01424-y

Other articles of this Issue 8/2019

Clinical Research in Cardiology 8/2019 Go to the issue